

# Keep Patients on Acamprosate Through Relapse

BY TIMOTHY F. KIRN  
Sacramento Bureau

SCOTTSDALE, ARIZ. — Alcohol abusers who take acamprosate and relapse are still better off continuing to take the drug because they have an improved chance of achieving abstinence, company data show.

Pooled data from three separate, controlled trials of the drug suggest that almost three times more patients treated through

a relapse eventually achieve a period of abstinence, compared with controls, Dr. Eugene Schneider said in a poster presentation at the annual meeting of the American Academy of Addiction Psychiatry.

In the studies, most of the participants relapsed at some point. Of the 372 people treated with acamprosate (1,998 mg/day), 72% relapsed, and 85% of 375 placebo-control patients relapsed. One of the trials lasted 13 weeks, one lasted 48 weeks, and the third lasted 52 weeks.

Overall, 13% of the acamprosate-treated individuals who relapsed were subsequently abstinent for the remainder of the study and an additional 20% who relapsed were abstinent at their final study evaluation. The comparable figures for the control patients were 5% and 10%, respectively, said Dr. Schneider, an associate director for medical affairs at Forest Laboratories Inc., New York.

Acamprosate-treated patients who achieved a period of abstinence after re-

lapse had a greater mean number of days of abstinence than did controls: 24 days vs. 14 days. In the patients who relapsed but eventually became abstinent for the remainder of the study, the treated patients were more likely to have had a longer abstinence: a mean of 28 days for the treated patients, compared with 12 days for the control patients.

"It is worthwhile treating patients through a relapse," Dr. Schneider said in an interview. ■

**FIRST**  
IN A NOVEL  
CLASS OF  
**SLEEP**  
AGENTS

NONSCHEDULED ROZEREM—

# ZERO

EVIDENCE OF ABUSE OR DEPENDENCE

Clinical studies show no evidence  
of potential abuse,\* dependence, or withdrawal

- **First and only**—nonscheduled prescription insomnia medication...not a controlled substance and approved for long-term use<sup>1</sup>
- **First and only**—prescription insomnia medication that targets the normal sleep-wake cycle<sup>1</sup>
- **First and only**—prescription insomnia medication with no evidence of abuse potential in clinical studies<sup>1</sup>
- **First and only**—prescription insomnia medication that does not act by CNS depression<sup>1</sup>
- **Promote sleep with Rozerem**—patients who took Rozerem fell asleep faster than those who took placebo<sup>1</sup>

Please visit [www.rozerem.com](http://www.rozerem.com)

\*A randomized, single-center, double-blind, dose run-up study (N=6) and a single-center, randomized, double-blind, placebo-controlled crossover study (N=14) specifically assessed the abuse liability of Rozerem in patients with a history of substance abuse.<sup>2</sup>

Rozerem is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Rozerem can be prescribed for long-term use. Rozerem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Rozerem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Exercise caution if consuming alcohol in combination with Rozerem. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Rozerem should not be taken with or immediately after a high-fat meal. Rozerem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Rozerem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

Please see adjacent Brief Summary of Prescribing Information.

 **Rozerem**<sup>™</sup>  
ramelteon 8-mg tablets

Proven for sleep.  
Nonscheduled for added safety.

Rozerem<sup>™</sup> is a trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc.